Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of DWP16001 (Enavogliflozin) Formulations in Healthy Volunteers
NCT05414591Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration and Maximum Plasma Concentration. Started May 2021; status: completed.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05414591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414591.